1-16 of 16
Tobias Kampfenkel
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Pharmacodynamic Signatures and Correlatives of Response in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Talquetamab or Teclistamab Plus Daratumumab and Pomalidomide

Free
Deeksha Vishwamitra, Sheri Skerget, Diana Cortes, Kalpana Bakshi, Lien Vandenberk, Weili Sun, Jaszianne Tolbert, Colleen Kane, Hein Ludlage, Bas D Koster, Julie S Larsen, Tobias Kampfenkel, Ching Li, Farheen Zishan, Thomas Prior, Luciano J. Costa, Jesus G Berdeja, Cyrille Touzeau, Aurore Perrot, Emma Searle, Jeffrey V Matous, Ajai Chari, Donna Reece, Manisha Bhutani, Bhagirathbhai Dholaria, Anita D'Souza, Thomas G Martin, John T. McKay, Alfred L Garfall, Amrita Y Krishnan, Niels W.C.J. van de Donk, Nizar J. Bahlis, Ricardo M. Attar
Journal: Blood
Blood (2024) 144 (Supplement 1): 594.
https://doi.org/10.1182/blood-2024-200300
Published: 2024
Journal Articles

Teclistamab, Daratumumab, and Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Results from the Majestec-2 Cohort a and Trimm-2 Studies

Free
Anita D'Souza, Luciano J. Costa, Jesús F. San-Miguel, Jesus G Berdeja, Daniel Morillo Giles, Cyrille Touzeau, John T McKay, Bhagirathbhai Dholaria, Thomas G Martin, Aurore Perrot, Albert Oriol, Anna Sureda Balari, Thomas Prior, Debopriya Ghosh, Lijuan Kang, Julie S Larsen, Hein Ludlage, Lien Vandenberk, Lingling Chen, Bas D Koster, Weili Sun, Rachel Kobos, Emma Searle, Jeffrey V Matous, Ajai Chari, Tobias Kampfenkel
Journal: Blood
Blood (2024) 144 (Supplement 1): 495.
https://doi.org/10.1182/blood-2024-200181
Published: 2024
Journal Articles

Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial

Free
Marc S. Raab, Niels Weinhold, K. Martin Kortüm, Jan Krönke, Lilli Podola, Uta Bertsch, Jan H. Frenking, Julia Mersi, Stefanie Huhn, Michael Hundemer, Gunhild Mechtersheimer, Roland Fenk, Katja C. Weisel, Natalie Schub, Florian Bassermann, Monika Engelhardt, Raphael Teipel, Mathias Hänel, Hans Salwender, Bas D Koster, Elena Ershova, Caline Sakabedoyan, Isobel Barrott, Agnes Balogh, Sanjay Vara, Tobias Kampfenkel, Hartmut Goldschmidt, Hermann Einsele, Leo Rasche
Journal: Blood
Blood (2024) 144 (Supplement 1): 493.
https://doi.org/10.1182/blood-2024-206003
Published: 2024
Journal Articles

Pharmacodynamic Profiles of Patients (Pts) with Newly Diagnosed (ND) Vs Relapsed/Refractory Multiple Myeloma (RRMM) Who Received Teclistamab (Tec) or Talquetamab (Tal) Plus Daratumumab (Dara) and Lenalidomide (Len) in the Phase 1b Majestec-2 and Monumental-2 Studies

Free
Diana Cortes, Brendan Paul Hodkinson, Ashwini Kumar, Sheri Skerget, Gary E Mason, Elizabeth Shearin, Hein Ludlage, Bas D Koster, Colleen Kane, Thomas Renaud, Tobias Kampfenkel, Christoph Heuck, Bhoomika Thakkar, Farheen Zishan, Emma Searle, Hang Quach, Gayathri Ravi, Cyrille Hulin, Wojciech Janowski, Jesus G Berdeja, Sébastien Anguille, Jeffrey V Matous, Cyrille Touzeau, Anne-Sophie Michallet, Ajay K. Nooka, Tara Cochrane, Anita D'Souza, Peter M. Voorhees, Karthik Ramasamy, Aurore Perrot, Andrew Spencer, Gurdeep Parmar, Deeksha Vishwamitra
Journal: Blood
Blood (2024) 144 (Supplement 1): 4653.
https://doi.org/10.1182/blood-2024-200333
Published: 2024
Journal Articles

Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Overall Survival Results from the Phase 3 Apollo Study

Free
Meletios A. Dimopoulos, Evangelos Terpos, Mario Boccadoro, Sosana Delimpasi, Meral Beksac, Eirini Katodritou, Philippe Moreau, Luca Baldini, Argiris Symeonidis, Jelena Bila, Albert Oriol, Maria-Victoria Mateos, Hermann Einsele, Ioannis Orfanidis, Tobias Kampfenkel, Weiping Liu, Michele Kosh, NamPhuong Tran, Robin Carson, Pieter Sonneveld
Journal: Blood
Blood (2022) 140 (Supplement 1): 7272–7274.
https://doi.org/10.1182/blood-2022-163483
Published: 2022
Journal Articles

MajesTEC-7: A Phase 3, Randomized Study of Teclistamab + Daratumumab + Lenalidomide (Tec-DR) Versus Daratumumab + Lenalidomide + Dexamethasone (DRd) in Patients with Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant

Free
Amrita Y. Krishnan, Salomon Manier, Evangelos Terpos, Saad Usmani, Josephine Khan, Rachel Pearson, Suzette Girgis, Yue Guo, Dana McAleer, Yunsi Olyslager, Tobias Kampfenkel, Niels W.C.J. van de Donk
Journal: Blood
Blood (2022) 140 (Supplement 1): 10148–10149.
https://doi.org/10.1182/blood-2022-160173
Published: 2022
Journal Articles

Pomalidomide and Dexamethasone with or without Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Updated Analysis of the Phase 3 Apollo Study

Free
Pieter Sonneveld, Evangelos Terpos, Mario Boccadoro, Sosana Delimpasi, Meral Beksac, Eirini Katodritou, Philippe Moreau, Luca Baldini, Argiris Symeonidis, Jelena Bila, Albert Oriol, Maria-Victoria Mateos, Hermann Einsele, Ioannis Orfanidis, Tobias Kampfenkel, Yanping Qiu, Himal Amin, Michele Kosh, NamPhuong Tran, Robin Carson, Meletios A. Dimopoulos
Journal: Blood
Blood (2021) 138 (Supplement 1): 2747.
https://doi.org/10.1182/blood-2021-146907
Published: 2021
Journal Articles

Daratumumab (DARA) with Bortezomib, Thalidomide, and Dexamethasone (VTd) in Transplant-Eligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) Negativity in Cassiopeia Part 1 and Part 2

Free
Herve Avet Loiseau, Pieter Sonneveld, Philippe Moreau, Fritz Offner, Vincent H.J. van der Velden, Denis Caillot, Cyrille Hulin, Bertrand Arnulf, Jill Corre, Mohamad Mohty, Lionel Karlin, Jérôme Lambert, Margaret Macro, Aurore Perrot, Mark-David Levin, Saskia K. Klein, Anne-Marie Stoppa, Michel Delforge, Sonja Zweegman, Kon-Siong Jie, Niels W.C.J. Van De Donk, Maria Krevvata, Fabio Rigat, Shiyi Yang, Veronique Vanquickelberghe, Carla de Boer, Tobias Kampfenkel, Jessica Vermeulen, Soraya Wuillème, Annemiek Broyl, Marie C Bene
Journal: Blood
Blood (2021) 138 (Supplement 1): 82.
https://doi.org/10.1182/blood-2021-147897
Published: 2021
Journal Articles

Indirect Treatment Comparisons of Daratumumab, Pomalidomide, and Dexamethasone Versus Daratumumab, Bortezomib, and Dexamethasone or Bortezomib and Dexamethasone in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma

Free
Jianming He, Heather Berringer, Bart Heeg, Tobias Kampfenkel, Harikumaran R. Dwarakanathan, Stephen Johnston, João Mendes, Annette Lam, Sacheeta Bathija, Eric Mackay
Journal: Blood
Blood (2021) 138 (Supplement 1): 4083.
https://doi.org/10.1182/blood-2021-146044
Published: 2021
Journal Articles

Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Free
Meletios A. Dimopoulos, MD, Evangelos Terpos, MD PhD, Mario Boccadoro, Sosana Delimpasi, MD, Meral Beksac, MD, Eirini Katodritou, MD, Philippe Moreau, MD, Luca Baldini, MD PhD, Argiris Symeonidis, MD PhD, Jelena Bila, Albert Oriol, Maria-Victoria Mateos, MD PhD, Hermann Einsele, MD, Ioannis Orfanidis, Tahamtan Ahmadi, MD PhD, Jon Ukropec, PhD, Tobias Kampfenkel, MD, Jordan Schecter, Yanping Qiu, Himal Amin, Jessica Vermeulen, MD PhD, Robin Carson, MD BA, Pieter Sonneveld, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 5–6.
https://doi.org/10.1182/blood-2020-135874
Published: 2020
Journal Articles

Real-World Use of Maintenance Therapy and Associated Outcomes Following Autologous Stem Cell Transplant in US Patients with Newly Diagnosed Multiple Myeloma

Free
Eric M. Ammann, PhD, Annette Lam, MSc, Wenze Tang, MPH, Tobias Kampfenkel, MD, Mohit Sharma, Charlene Lee, MSc, Shuchita Kaila, PhD, Alex Z. Fu, PhD, Kathleen Gray, PhD, Jianming He, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 25–26.
https://doi.org/10.1182/blood-2020-139882
Published: 2020
Journal Articles

Impact of Modified Thalidomide Dosing in Bortezomib/Thalidomide/Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant-Eligible: A Matching-Adjusted Indirect Comparison

Free
Pieter Sonneveld, Maria-Victoria Mateos, MD PhD, Adrián Alegre, MD, Thierry Facon, MD, Cyrille Hulin, MD, Mahmoud Hashim, Talitha Vincken, Tobias Kampfenkel, MD, Sarah Cote, Philippe Moreau, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4739.
https://doi.org/10.1182/blood-2019-122775
Published: 2019
Journal Articles

Comparative Efficacy and Safety of Bortezomib, Thalidomide, and Dexamethasone (VTd) without and with Daratumumab (D-VTd) from Cassiopeia Versus Vtd from Pethema/GEM in Patients with Newly Diagnosed Multiple Myeloma Using Propensity Score Matching (PSM)

Free
Philippe Moreau, MD, Cyrille Hulin, MD, Sonja Zweegman, MD PhD, Yannan Hu, PhD, Bart Heeg, PhD, Mahmoud Hashim, Carla de Boer, Veronique Vanquickelberghe, Tobias Kampfenkel, MD, Annette Lam, Sarah Cote, Pieter Sonneveld
Journal: Blood
Blood (2019) 134 (Supplement_1): 4740.
https://doi.org/10.1182/blood-2019-123491
Published: 2019
Journal Articles

Evaluation of the Prognostic Value of Positron Emission Tomography-Computed Tomography (PET-CT) at Diagnosis and Follow-up in Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients Treated in the Phase 3 Cassiopeia Study: Results of the Cassiopet Companion Study

Free
Philippe Moreau, MD, Sonja Zweegman, Aurore Perrot, MD PhD, Cyrille Hulin, MD, Denis Caillot, MD, Thierry Facon, MD, Xavier Leleu, MD PhD, Karim Belhadj, Lionel Karlin, MD, Lotfi Benboubker, MD, Mark-David Levin, MD PhD, Monique C. Minnema, MD PhD, Bastien Jamet, Caroline Bodet-Milin, Pieter Sonneveld, Jérôme Lambert, Lixia Pei, Carla de Boer, Jessica Vermeulen, MD PhD, Tobias Kampfenkel, MD, Francoise Kraeber-Bodere
Journal: Blood
Blood (2019) 134 (Supplement_1): 692.
https://doi.org/10.1182/blood-2019-123143
Published: 2019
Journal Articles

An Adjusted Treatment Comparison of Bortezomib/Cyclophosphamide /Dexamethasone and Bortezomib/Thalidomide/Dexamethasone from Real-World Data in Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant-Eligible

Free
Maneesha Mehra, Sarah Cote, Tobias Kampfenkel, MD, Sandhya Nair
Journal: Blood
Blood (2019) 134 (Supplement_1): 2142.
https://doi.org/10.1182/blood-2019-123512
Published: 2019
Journal Articles

Comparative Efficacy and Safety of Daratumumab in Combination with Bortezomib, Melphalan, and Prednisone (D-VMP) in Alcyone Versus Bortezomib, Melphalan, and Prednisone (VMP) in Vista in Newly Diagnosed Multiple Myeloma (NDMM) Patients Using Propensity Score Matching (PSM)

Free
Michele Cavo, MD, Meletios A Dimopoulos, MD, Jesus F San-Miguel, MD PhD, Maria-Victoria Mateos, MD PhD, Andrzej Jakubowiak, MD PhD, William Deraedt, Annette Lam, Tobias Kampfenkel, MD, Ming Qi, MD PhD, Jianming He, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3550.
https://doi.org/10.1182/blood-2018-99-113128
Published: 2018